Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine Hydrochloride, the active ingredient in Mydriasert, is a mydriatic agent presented as an ophthalmic solution for ocular use. Combined with Tropicamide, it produces rapid and sustained pupil dilation for diagnostic eye examinations and pre‑operative ophthalmic procedures.

GNH USA supplies Mydriasert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is distributed to eye‑care facilities across multiple continents. Its quality is ensured through rigorous manufacturing controls and batch testing.

Mydriasert, a mydriatic ophthalmic solution, is used to induce pharmacologic pupil dilation for ocular diagnostic and surgical procedures.

- Eye examinations: provides adequate pupil dilation for detailed retinal evaluation. - Fundus photography: enables clear imaging of the retina and optic nerve. - Pre‑operative preparation: produces sustained mydriasis for intra‑ocular surgery.

Mydriasert may cause ocular and systemic adverse reactions following topical administration.

Common Side Effects: - Transient ocular redness - Mild eye irritation or burning sensation - Temporary blurred vision - Slight increase in intra‑ocular pressure in susceptible eyes

Serious or Rare Side Effects: - Acute angle‑closure glaucoma - Systemic hypertension - Allergic contact dermatitis - Severe ocular pain

Before using Mydriasert, consider the following precautions. - Assess intra‑ocular pressure before use: avoid in patients with narrow‑angle glaucoma. - Avoid use in patients with known hypersensitivity to phenylephrine or tropicamide. - Use the lowest effective concentration: limit exposure to reduce systemic absorption. - Monitor blood pressure in patients with cardiovascular disease. - Store at room temperature: keep in the original container, protect from light and moisture.

Mydriasert can interact with other medicines; review the following.

Major Interactions (Avoid): - Systemic sympathomimetics (e.g., oral phenylephrine): may cause additive hypertensive effects. - Monoamine oxidase inhibitors: increased risk of hypertensive crisis. - Other mydriatics: excessive pupil dilation. - Anticholinergic drugs: enhanced cycloplegic effect.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt systemic cardiovascular response. - Topical anesthetics: may increase corneal toxicity. - Systemic antihypertensives: monitor blood pressure.